Clinical effectiveness analysis of dextran 40 plus dexamethasone on the prevention of fat embolism syndrome.

Abstract

This study aims to investigate the clinical efficacy of Dextran 40 plus dexamethasone on the prevention of fat embolism syndrome (FES) in high-risk patients with long bone shaft fractures. According to the different preventive medication, a total of 1837 cases of long bone shaft fracture patients with injury severity score (ISS) > 16 were divided into four groups: dextran plus dexamethasone group, dextran group, dexamethasone group and control group. The morbidity and mortality of FES in each group were analyzed with pairwise comparison analysis. There were totally 17 cases of FES and 1 case died. The morbidity of FES was 0.33% in dextran plus dexamethasone group and significantly lowers than that of other groups (P < 0.05). There was no significant difference among other groups (P > 0.05). Conclusion from our data is dextran 40 plus dexamethasone can effectively prevent long bone shaft fractures occurring in high-risk patients with FES.

• Authors: Xi-Ming Liu, Jin-Cheng Huang, Guo-Dong Wang, Sheng-Hui Lan, Hua-Song Wang, Chang-Wu Pan, Ji-Ping Zhang, Xian-Hua Cai
• Journal: International journal of clinical and experimental medicine (Int J Clin Exp Med) Vol. 7 Issue 8 Pg. 2343-6 ( 2014) ISSN: 1940-5901 [Print] United States
• PMID: 25232433 (Publication Type: Journal Article)